Mitral regurgitation is a cardiovascular condition characterized by the backward flow of blood from the left ventricle into the left atrium of the heart. This occurs when the mitral valve, responsible for regulating blood flow between these chambers, does not close properly during each heartbeat. The inefficient closure leads to a leakage of blood, causing the heart to work harder to pump a sufficient amount of blood to meet the body's needs. Mitral regurgitation can result from various causes, such as mitral valve prolapse, rheumatic heart disease, or congenital abnormalities. Common symptoms include fatigue, shortness of breath, and a distinct heart murmur. Timely diagnosis and intervention are crucial to prevent complications and manage the condition effectively, often involving medications or, in severe cases, surgical repair or replacement of the mitral valve. Management strategies aim to alleviate symptoms, improve heart function, and enhance overall quality of life for individuals affected by mitral regurgitation. Regular monitoring and collaboration with healthcare professionals are key aspects of managing this cardiovascular condition.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India